Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00914537 · ClinicalTrials.gov registry record

Anal Cancer Screening Study

A clinical trial, sponsored by National Cancer Institute (NCI).

Completed
Registry status
363
Enrollment target

NCT00914537: Completed study, sponsored by National Cancer Institute (NCI).

NCT00914537 is a clinical trial that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 363 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT00914537 has completed, sponsored by National Cancer Institute (NCI).

COMPLETED
Registry status
363 participants
Enrollment target

Study Summary

Background: * HIV-positive men who have sex with men (MSM) have rates of anal cancer that approach those of cervical cancer in women. However, unlike cervical cancer, there is no current recommended method of screening that could be used to detect anal precancerous lesions for the prevention of anal cancer in HIV-positive MSM. * Infections by human papillomavirus (HPV) are the likely cause of cervical and anal precancer and cancer. Detecting the presence of HPV or related biomarkers has helped to identify women who may be at increased risk of cervical cancer; researchers believe that early detection of HPV or related biomarkers in MSM may be useful for anal cancer screening. Objectives: \- To evaluate the effectiveness of various tests to detect cancer-causing HPV in HIV-positive men who have sex with men. Eligibility: \- HIV-positive MSM that are interested in receiving anal screening for precancer Design: * HIV-positive MSM will respond to a self-administered risk factor questionnaire, and will undergo a physical exam and a high-resolution anoscopy at the participating clinic. * The clinician will then collect to anal Pap specimens from each subject for research on HPV and related biomarkers. * Participants will be followed annually for 2 years to collect additional health data for research follow-up.

Primary Outcome

Detection of AIN2 and AIN3 in high resolution anoscopy

Trial Details

FieldValue
Enrollment Target 363 participants
Start Date 2009-06-02
Est. Completion 2020-11-04
National Cancer Institute (NCI)

3,257 total trials

What the finished NCT00914537 record still lists

NCT00914537 is an observational study that tracks outcomes without assigning an intervention. The registered 363 participants enrollment target is mid-sized for trials with a published cap.

The record links to 0 conditions, and to 0 interventions.

NCT00914537 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00914537 about?

NCT00914537 is a clinical study titled "Anal Cancer Screening Study". Background: * HIV-positive men who have sex with men (MSM) have rates of anal cancer that approach those of cervical cancer in women. However, unlike cervical cancer, there is no current recommended method of screening that could be used to detect anal precancerous lesions for the prevention of ana...

What is the current status of trial NCT00914537?

This trial is currently completed. The enrollment target is 363 participants. The study started on 2009-06-02. Estimated completion is 2020-11-04.

Who is sponsoring clinical trial NCT00914537?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT06472245 · 363 participants · Phase 3

    Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor

  • NCT04510597 · 364 participants · Phase 3

    Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial

  • NCT05098132 · 364 participants · Phase 1

    Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers

  • NCT05330221 · 364 participants · NA

    Project 2: ACHIEVE- HF

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT00914537, the US trial registry maintained by the National Library of Medicine. NCT00914537 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.